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ACUTE HEMODYNAMIC EFFECTS OF CARVEDILOL VERSUS 
METOPROLOL IN IDIOPATHIC DILATED CARDIOMYOPATHY 
, Edward M. Gilbert, Stephanie L. Olsen, Patrice 
I R. Btistow. Division of Cardiology, University of 
Utah Medical Center, Salt Lake City. UT. 
Carvedilol (C) is a mildly selective 0, blocking agent with 
vasodilator properties via qblockade. Because of this vasodilator 
property, C may be better tolerated in dilated cardiomyopathy than 
"pure" &blockers such as mesprolol (M). Ws rested this hypothesis 
by comparing the acute hemodynamic effects ofC and M. Drugs were 
randomly given in a oral dose of 6.25 mg q 12 hours and pts were 
monitored for 24 hours. Both drugs were well tolerated with no side 
effects. Data from baseline were compared to combined data collected 
2 and 4 hours after both doses and are given as x*SD (* ~~0.05; # 
p1;0.01). 
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LEGEND: HR=heart rate; MAP=mean arterial pressure; MPAP= 
mean pulmonary artery pressure; MPAWP=mean pulmonary artery 
wedge pressure; CI= cardiac index; SVR=systemic vascular 
: 1) M and C had similar heart rate effects suggesting 
a similar degree of O-blockade; and 2)C but not M reduced systemic 
blood pressure, systemic vascular resistance and LV filling pressure, 
indicating a direct vasodilator effect. These effects would be expected 
to be beneficial in heart failure. 
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Steven Burstein #BBcE, Hart J. Semigran MD, G. William 
bet UD FACC, Charles A. Boucher IiD FACC, Michael A. Fifer 
MD FACC. Massachusetts General 
Medical School, Boston, nA 
Hospital and tlarvard 
We have recently shown that flosequinan, a nev drug 
for heart failure, has a positive inotropic affect in 
addition to its vasodilator action. To determine vhether 
flosequinan also influences q yocardial isovolumic 
relaxation, ve measured left ventricular (LV) 
micromanometer pressure in 14 patients vith heart failure 
(NYIU Class III-IV, EF(0.40) at baseline and during 
administration of flosequinan, 150 intravenously. 
Mean arterial pressure fell from 9223 to 85*3 mm& 
(meantS&!, p<.OS) on flosequinan, and heart rate 
increased from 9324 to 99*3 beats/min (p<.OS). Plasma 
norepinephrine and epinephrine levels vere unchanged on 
flosequinan. LV end-diastolic pressure (EDP, mmHg), LV 
peak negative dP/dt (-dP/dt, mmIig/sec), and the time 
constant of isovolumic relaxation, determined by the 
logarithmic (TL, q see) and derivaiive (TD, q secj methods, 
vere (*p<.OS): 
Baseline 
Flosequinen 
LVEDP -dP/dt XL TD 
31i2 -912*70 9&B 102i3 
2&3* -X056273* 70*6* 84&6* 
conclusion: Flosequinan improves LV isovolumic 
relaxation in patients vith heart failure. Thus, like 
beta adrenergic agonists and phophodiesterase inhibitors, 
flosequinan has both positive inotropic and positive 
“lusitropic” effects. 
VALIDATION OF PREOPERATIVE ECHO FINDINGS IN 
PATIENTS UNDERGOING MITRAL VALVE REPAIR 
Joe F. Malouf, Carlos Duran, Ricardo Gallo, Nil- 
tiadis Stefadouros, King Fahad Hospital and King 
Faisal Specialist Hospital, Riyadh, Saudi Arabia. 
Decision regarding suitability for repair of a 
diseased mitral valve (MV) is based on certain 
morphological features of the MV apparatus obser- 
ved at surgery. To determine whether these feat- 
ures can be detected by echo, we performed preop 
validation studies using transthoracic and trans- 
esophageal 2-D echo on 50 Pts undergoing MV rep- 
air in whom subsequent direct observations were 
made at surgery in a double-blind fashion. 
Results: The (%) 
ative (PV- P 
redictive value positive (PVt) 
and the accuracy (ACC) for 
LA thrombus, all wbre 100. Corresponding PV*, 
PV- and ACC were: For anterior cusp: thickening 
~~~~9"3B"'~i~~~~~~~'~~~~~o~~~~o~~~~~o~~~~~~~~D~~~l 
93,65).'and retrac;ion'(I,i2,92j. For posterio; 
cusp: thickening (93,50,91), calcification (100, 
g3,93), mobiilty (130,81,86), billowing (1,100, 
100). prolapse (1,300,100) and retraction (80. 
71,72). PV+, PV- and ACC for anterior and post- 
erior commissural fusion and calcification rano- 
ed from 87 to 100. Conclusion: Observations on" 
the detailed echo anatomv of the MV are suffic- 
iently predictive and aciurate to be of potent- 
ial value to the surgeon in selecting patients 
suitable for MV repair. 
*I I ndeterminate due to lack of positives in the 
S ample. 
CLINICAL TCOME AFTER DYNAMIC CARD10 
FOR TREA EN1 OF HEART FAILURE DUE TO 
DILATED CARDIOMYOPATHY OR CHAGAS’ S DISEASE 
Edimar Bocchi, Luis F. Moreira, Giovanni Bellotti, Antonio P. 
Barreto, Noedir Stolf Adib Jatene, Fulvio Pileggi - lnstituto do 
Corac5o, University of Slo Paulo, BRAZIL. 
The detailed clinical outcome after dynamic cardiomyoplasty (CMP) 
has yet to be described. We studied 15 PT, 43 f 12 years old, 
13 male, mean follow-up of 12 f 8 months (MI, ejection 
fraction (%I by echocardiographic study 30 t 6 submitted to 
CMP for treatment of heart failure (HF) (III - 10 PT, IV - 5 PT, 
NYHA) due to idiopathic dilated cardiomyopathy (13 PT) or 
Chagas’ s d&a&e (2 PT). The medications used for treatment of 
HF were: diuretics (40 - 80 mg of furosemide, digoxin, potassium 
supplementation and angiotensin - converting enzyme inhibitor). 
We analysed the morbidity, the mortality, the functional class 
and working capacity in the immediate post - operdtive period 
and in the late follow - up. In the immediate post - operative 
period there were: necessity for transitory inotropic drugs e.v. 
infusion in all PT. sustained ventricular techycardia (1 PTI, ecute 
atrial fibrillation (1 PT), incision infection (1 PT), pulmonary 
infection (1 PT), transitory brachial plexus lesion (1 PT), increment 
of bilirubin levels (2 PT) and one death due to muscle &hernia 
and heart failure. In the late follow-up: 1 PT developed arterial 
hypertension (unknown mechanism), one acute atrial fibrillation 
episode (1 PT), and one mitral valve surgery at 11 M after 
CMP for treatment of mitral regurgitation (1 PT). There were 
three deaths due to: pulmonary embolism and infection (1 PT), 
HF and acute renal failure (1 PT - waiting heart transplantation) 
and HF and infection (1 PT). The mortality at 1, 6 and 12 M were 
7% a& 20%. respectively. At this moment, there are 6 PT in II 
and 5 PT in I NYHA class functional, and 8 of them are working. 
In 6 of these PT, the diuretic dosages were reduced. Conclusion: In 
spite of some mortality and morbidity, the PT after CMP improved 
their functional class and most returned to their joba CMP can be an 
therapeutic option in heart failure treatment in order to improve the 
quality of life. 
